Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

GPs can start treatment with certain heart failure drugs that previously had to be initiated by a specialist, NICE has said in updated guidance. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and ...

The PARADIGM‐HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial revealed that a combined angiotensin receptor blocker (ARB, ...

In the PARAGON-HF trial (Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), sex and left ventricular ejection fraction appeared to modify the ...

Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual ...

References: Narayanan K, Reinier K, Teodorescu C, et al. Left ventricular diameter and risk stratification for sudden cardiac death. J Am Heart Assoc. 2014;3(5 ...

Mitral regurgitation (MR) and tricuspid regurgitation (TR) are the most common valvular heart diseases (VHDs) in patients with heart failure (HF). 1–8 Their prognostic role has been established, 2,4,6 ...

Background—Treatments that reduce mortality and morbidity in patients with heart failure with ... Heart Failure Vol. 10, No. 1 Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic ...

Patients whose heart function improves after being treated for heart failure may feel better, but stopping their medications could still put them at serious risk. A new study from the Karolinska ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals’ treatment for a progr ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035.This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...